Details of the Drug

General Information of Drug (ID: DM49DUI)

Drug Name
Tretinoin
Synonyms
Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1], [2]
Acute promyelocytic leukaemia 2A60.0 Approved [3]
Therapeutic Class
Keratolytic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 300.4
Topological Polar Surface Area (xlogp) 6.3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 - 2 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.70165 micromolar/kg/day [7]
Chemical Identifiers
Formula
C20H28O2
IUPAC Name
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
Canonical SMILES
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
InChI
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
InChIKey
SHGAZHPCJJPHSC-YCNIQYBTSA-N
Cross-matching ID
PubChem CID
444795
ChEBI ID
CHEBI:15367
CAS Number
302-79-4
DrugBank ID
DB00755
TTD ID
D02DGU
VARIDT ID
DR00154
INTEDE ID
DR1634
ACDINA ID
D00699

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor (RAR) TTOD7B3 NOUNIPROTAC Binder [8]
Retinoic acid receptor gamma (RARG) TT1Q3IE RARG_HUMAN Agonist [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [11]
Cytochrome P450 26C1 (CYP26C1) DEXNDR0 CP26C_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Retinoic acid receptor gamma (RARG) DTT RARG 5.43E-04 -0.14 -0.37
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tretinoin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Isotretinoin DM4QTBN Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and Isotretinoin. Acne vulgaris [ED80] [89]
Sarecycline DMLZNIQ Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and Sarecycline . Acne vulgaris [ED80] [90]
Coadministration of a Drug Treating the Disease Different from Tretinoin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [91]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Tretinoin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [92]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [93]
Posaconazole DMUL5EW Moderate Decreased metabolism of Tretinoin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [94]
Ofloxacin DM0VQN3 Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [95]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Tretinoin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [94]
Sparfloxacin DMB4HCT Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [95]
Gemifloxacin DMHT34O Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [95]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [95]
ABT-492 DMJFD2I Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [95]
Omadacycline DMR2J95 Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and Omadacycline. Bacterial infection [1A00-1C4Z] [90]
Levofloxacin DMS60RB Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [95]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Tretinoin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [94]
Minocycline DMVN5OH Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and Minocycline. Bacterial infection [1A00-1C4Z] [90]
Lomefloxacin DMVRH9C Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [95]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Tretinoin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [94]
Tetracycline DMZA017 Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and Tetracycline. Bacterial infection [1A00-1C4Z] [90]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Tretinoin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [96]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Tretinoin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [97]
Tucatinib DMBESUA Moderate Decreased metabolism of Tretinoin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
Mifepristone DMGZQEF Moderate Decreased metabolism of Tretinoin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [91]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Tretinoin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [98]
MK-8228 DMOB58Q Moderate Decreased metabolism of Tretinoin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [99]
Vilazodone DM4LECQ Moderate Decreased metabolism of Tretinoin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [100]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Tretinoin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [94]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Tretinoin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Cenobamate DMGOVHA Moderate Increased metabolism of Tretinoin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Rufinamide DMWE60C Moderate Increased metabolism of Tretinoin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [89]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Cannabidiol. Epileptic encephalopathy [8A62] [89]
Itraconazole DMCR1MV Major Decreased metabolism of Tretinoin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [94]
Ketoconazole DMPZI3Q Major Decreased metabolism of Tretinoin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [94]
Ripretinib DM958QB Moderate Decreased metabolism of Tretinoin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [91]
Boceprevir DMBSHMF Moderate Decreased metabolism of Tretinoin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Telaprevir DMMRV29 Moderate Decreased metabolism of Tretinoin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Rifapentine DMCHV4I Moderate Increased metabolism of Tretinoin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [103]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [104]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Tretinoin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Tretinoin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Saquinavir DMG814N Moderate Decreased metabolism of Tretinoin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Etravirine DMGV8QU Moderate Increased metabolism of Tretinoin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [105]
Darunavir DMN3GCH Moderate Decreased metabolism of Tretinoin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Atazanavir DMSYRBX Moderate Decreased metabolism of Tretinoin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Tretinoin and Mipomersen. Hyper-lipoproteinaemia [5C80] [107]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Tretinoin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [108]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Tretinoin and BMS-201038. Hyper-lipoproteinaemia [5C80] [109]
Conivaptan DM1V329 Moderate Decreased metabolism of Tretinoin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [94]
TP-434 DM5A31S Major Increased risk of pseudotumor cerebri by the combination of Tretinoin and TP-434. Infectious gastroenteritis/colitis [1A40] [90]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tretinoin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [110]
Brigatinib DM7W94S Moderate Increased metabolism of Tretinoin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [111]
Ceritinib DMB920Z Moderate Decreased metabolism of Tretinoin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [94]
PF-06463922 DMKM7EW Moderate Increased metabolism of Tretinoin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [112]
Selpercatinib DMZR15V Moderate Decreased metabolism of Tretinoin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [89]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [113]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Idelalisib. Mature B-cell leukaemia [2A82] [114]
IPI-145 DMWA24P Moderate Decreased metabolism of Tretinoin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [115]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Tretinoin caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [91]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Tretinoin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [89]
Exjade DMHPRWG Moderate Decreased metabolism of Tretinoin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [116]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Tretinoin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [89]
Nilotinib DM7HXWT Moderate Decreased clearance of Tretinoin due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [117]
Dasatinib DMJV2EK Moderate Decreased metabolism of Tretinoin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [118]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Tretinoin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [119]
Abametapir DM2RX0I Moderate Decreased metabolism of Tretinoin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [120]
Lefamulin DME6G97 Moderate Decreased metabolism of Tretinoin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [121]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Tretinoin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [94]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Tretinoin caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [108]
Gatifloxacin DMSL679 Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [95]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Tretinoin and Leflunomide. Rheumatoid arthritis [FA20] [108]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Tretinoin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [89]
Larotrectinib DM26CQR Moderate Decreased metabolism of Tretinoin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [91]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Tretinoin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [89]
Armodafinil DMGB035 Minor Increased metabolism of Tretinoin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [122]
LEE011 DMMX75K Moderate Decreased metabolism of Tretinoin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [123]
Fostamatinib DM6AUHV Moderate Decreased clearance of Tretinoin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [124]
Cinoxacin DM4EWNS Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [95]
Nalidixic acid DMRM0JV Minor Decreased absorption of Tretinoin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [95]
⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Ascorbyl palmitate E00581 54680660 Antioxidant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS E00309 24671 Colorant
Ammonia E00007 222 Alkalizing agent
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Nitrogen E00033 947 Aerosol propellant; Sparging agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Soybean lecithin E00637 Not Available Other agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tretinoin 10 mg capsule 10 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2644).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
9 Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9.
10 Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
11 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 CYP26C1 is a hydroxylase of multiple active retinoids and interacts with cellular retinoic acid binding proteins. Mol Pharmacol. 2018 May;93(5):489-503.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
25 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
26 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
27 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
28 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
29 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
30 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
31 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
32 Drug Interactions Flockhart Table
33 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
34 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
35 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
36 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
37 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
38 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
39 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
40 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
41 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
42 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
43 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
44 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
45 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
46 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
47 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
48 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
49 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
50 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
51 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
52 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
53 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
54 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
55 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
56 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
57 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
58 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
59 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
60 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
61 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
62 Drugs that may have potential CYP2B6 interactions.
63 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
64 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
65 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
66 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
67 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
68 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
69 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
70 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
71 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
72 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
73 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
74 Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
75 Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402.
76 A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4.
77 National Cancer Institute Drug Dictionary (drug id 39582).
78 Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191.
79 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7.
80 Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74.
81 Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32.
82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956)
83 An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8.
84 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
85 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
86 Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31.
87 Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12.
88 Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
89 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
90 Gardner K, Cox T, Digre KB "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology 45 (1995): 6-10. [PMID: 7824136]
91 Cerner Multum, Inc. "Australian Product Information.".
92 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
93 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
94 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
95 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
96 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
97 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
98 Cerner Multum, Inc. "Canadian Product Information.".
99 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
100 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
101 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
102 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
103 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
104 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
105 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
106 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
107 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
108 Canadian Pharmacists Association.
109 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
110 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
111 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
112 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
113 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
114 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
115 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
116 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
118 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
119 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
120 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
121 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
122 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
123 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
124 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.